The Pharma Data
MARCH 20, 2021
“Studies will embrace decentralized trial approaches as design options earlier in the clinical trial planning process,” Reites said. Sponsors and CROs will continue to be eager to bounce back and accelerate the drug development process after significant delays caused by the pandemic,” Reites said. .
Advarra
JUNE 28, 2022
As a drug successfully makes it through the development process, sponsors will inevitably need to submit a new drug application (NDA) to the Food and Drug Administration (FDA). Failure to Have a Pre-Investigational New Drug (IND) Meeting. Failure to Have a Pre-Investigational New Drug (IND) Meeting.
XTalks
JUNE 4, 2024
In the ever-evolving landscape of pharmaceutical development, the complexity of early phase clinical trials is increasing. This surge in complexity is driven by escalating drug development costs, heightened competition and advanced scientific innovations. This is the storm that we find ourselves in the midst of.”
Expert insights. Personalized for you.
52 
Let's personalize your content